A short-term (8 week) open-label study, followed by a long term evaluation, to assess patient-reported outcomes with armodafinil treatment (150 to 250 mg/day) for excessive sleepiness in adults with narcolepsy or obstructive sleep apnea/hypopnea syndrome

Trial Profile

A short-term (8 week) open-label study, followed by a long term evaluation, to assess patient-reported outcomes with armodafinil treatment (150 to 250 mg/day) for excessive sleepiness in adults with narcolepsy or obstructive sleep apnea/hypopnea syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2011

At a glance

  • Drugs Armodafinil (Primary)
  • Indications Narcolepsy; Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 24 Jun 2010 Actual patient number (247) added as reported by ClinicalTrials.gov.
    • 24 Jun 2010 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
    • 01 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top